Pralatrexate
Active ingredient: Pralatrexate
In short: Pralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate .
What is Pralatrexate used for?
Pralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
This indication is approved under accelerated approval based on overall response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Pralatrexate dosage
Pretreatment Vitamin Supplementation
Folic Acid
Instruct patients to take folic acid 1 to 1.25 mg orally once daily beginning 10 days before the first dose of pralatrexate injection. Continue folic acid during treatment with pralatrexate injection and for 30 days after the last dose .
Vitamin B12
Administer vitamin B12 1 mg intramuscularly within 10 weeks prior to the first dose of pralatrexate injection and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate injection .
The recommended dosage of pralatrexate injection is 30 mg/m2 intravenously over 3-5 minutes once weekly for 6 weeks in 7-week cycles until progressive disease or unacceptable toxicity.
Severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2 by MDRD): Reduce the pralatrexate injection dose to 15 mg/m2
.
End stage renal disease (ESRD: eGFR less than 15 mL/min/1.73 m2 by MDRD) with or without dialysis: Avoid administration. If the potential benefit of administration justifies the potential risk, monitor renal function and reduce the pralatrexate injection dose based on adverse reactions .
Monitoring
Monitor complete blood cell counts and severity of mucositis at baseline and weekly. Perform serum chemistry tests, including renal and hepatic function, prior to the start of the first and fourth dose of each cycle.
Recommended Dosage Modifications
Do not administer pralatrexate injection until:
Mucositis Grade 1 or less.
Platelet of 100,000/mcL or greater for first dose and 50,000/mcL or greater for all subsequent doses.
Absolute neutrophil count (ANC) of 1,000/mcL or greater.
Dosage modifications for adverse reactions are provided in Tables 1, 2, and 3. …
How to take Pralatrexate — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Folic Acid and Vitamin B12 Supplementation
Advise patients treated with pralatrexate injection to take folic acid and vitamin B12 to reduce the risk of possible side effects .
Myelosuppression
Inform patients of the risk of myelosuppression and to immediately contact their healthcare provider should any signs of infection develop, including fever. Inform patients to contact their healthcare provider if bleeding or symptoms of anemia occur .
Mucositis
Inform patients of the signs and symptoms of mucositis. Instruct patients on ways to reduce the risk of its development, and on ways to maintain nutrition and control discomfort from mucositis if it occurs .
Dermatologic Reactions
Advise patients about the risks for and the signs and symptoms of dermatologic reactions. Instruct patients to immediately notify their healthcare provider if any skin reactions occur .
Tumor Lysis Syndrome
Inform patients about the risk of and the signs and symptoms of tumor lysis syndrome. Patients should be instructed to notify their healthcare provider if they experience these symptoms . …
Warnings & precautions
Do not take this medicine if: None
Pralatrexate injection can cause myelosuppression, manifested by thrombocytopenia, neutropenia, and/or anemia.
Administer vitamin B12 and instruct patients to take folic acid to reduce the risk of treatment-related myelosuppression .
Monitor complete blood counts and omit and/or reduce the dose based on ANC and platelet count prior to each dose .
Pralatrexate injection can cause mucositis .
Administer vitamin B12 and instruct patients to take folic acid to reduce the risk of mucositis .
Monitor for mucositis weekly and omit and/or reduce the dose for grade 2 or higher mucositis .
Pralatrexate injection can cause severe dermatologic reactions, which may result in death. These dermatologic reactions have been reported in clinical studies (2.1% of 663 patients) and post marketing experience, and have included skin exfoliation, ulceration, and toxic epidermal necrolysis (TEN) . They may be progressive and increase in severity with further treatment and may involve skin and subcutaneous sites of known lymphoma.
Monitor closely for dermatologic reactions. Withhold or discontinue pralatrexate injection based on severity .
Pralatrexate injection can cause tumor lysis syndrome (TLS). Monitor patients who are at increased risk of TLS and treat promptly.
Pralatrexate injection can cause hepatic toxicity and liver function test abnormalities . Persistent liver function test abnormalities may be indicators of hepatic toxicity and require dose modification or discontinuation.
Monitor liver function tests. Omit dose until recovery, adjust or discontinue therapy based on the severity of the hepatic toxicity .
Patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2 based on MDRD) may be at greater risk for increased exposure and adverse reactions. Reduce pralatrexate injection dosage in patients with severe renal impairment . …
Pralatrexate side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Myelosuppression
Mucositis
Dermatologic Reactions
Tumor Lysis Syndrome
Hepatic Toxicity
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Peripheral T-cell Lymphoma
The safety of pralatrexate injection was evaluated in Study PDX-008 . Patients received pralatrexate injection 30 mg/m2 once weekly for 6 weeks in 7-week cycles. The median duration of treatment was 70 days (range: 1 day to 1.5 years). The majority of patients (69%, n = 77) remained at the target dose for the duration of treatment. Overall, 85% of scheduled doses were administered.
Forty-four percent of patients (n = 49) experienced a serious adverse event while on study or within 30 days after their last dose of pralatrexate injection. The most common serious adverse events (> 3%), regardless of causality, were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia. One death from cardiopulmonary arrest in a patient with mucositis and febrile neutropenia was reported in this trial. Across clinical trials, deaths from mucositis, febrile neutropenia, sepsis, and pancytopenia occurred in 1.2% of patients who received doses ranging from 30 mg/m2 to 325 mg/m2. …
Drug interactions
Coadministration of pralatrexate injection with probenecid increased pralatrexate plasma concentrations , which may increase the risk of adverse reactions. Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. If coadministration is unavoidable, monitor for increased risk of adverse reactions.
About this medicine
Pralatrexate is a dihydrofolate reductase inhibitor. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3- ynyl]benzoyl]amino]pentanedioic acid. The molecular formula is C23H23N7O5 and the molecular weight is 477.48 g/mol. Pralatrexate is a 1:1 racemic mixture of S- and R- diastereomers at the C10 position (indicated with *). The structural formula is as follows:
Pralatrexate is an off-white to yellow hygroscopic powder. The pH is 4.45 (in 1% aqueous suspension). Pralatrexate is soluble in dimethyl sulfoxide and sparingly soluble in dimethyl formamide. The pKa values are 3.25, 4.70, and 6.
Pralatrexate injection is supplied as a preservative-free, sterile, isotonic, non-pyrogenic clear yellow aqueous solution contained in a clear glass single-dose vial (Type I) for intravenous use. Each 1 mL of solution contains 20 mg of pralatrexate, 6.4 mg of sodium chloride to achieve an isotonic (280-300 mOsm) solution, and sufficient sodium hydroxide, and hydrochloric acid if needed, to adjust and maintain the pH at 7.5-8.5. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cc3df863-c51c-49c5-283a-d6808fb49258. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate